SAN FRANCISCO, Feb. 26, 2016 /PRNewswire/ -- Nektar Therapeutics
(Nasdaq: NKTR) will announce its financial results for the fourth
quarter and year-ended December 31,
2015, on Tuesday, March 1,
2016, after the close of U.S.-based financial markets.
Howard Robin, president and chief
executive officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time (ET)/2:00 p.m. Pacific
Time (PT).
The press release and a live audio-only Webcast of the
conference call can be accessed through a link that is posted on
the home page and Investor Relations section of the Nektar website:
http://www.nektar.com. The web broadcast of the conference call
will be available for replay through Friday,
April 1, 2016.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 50771255 (Nektar Therapeutics is the host)
About Nektar
Nektar Therapeutics has a robust R&D pipeline in pain,
oncology, hemophilia and other therapeutic areas. In the area of
pain, Nektar has an exclusive worldwide license agreement
with AstraZeneca for MOVANTIK™ (naloxegol), the
first FDA-approved once-daily oral peripherally-acting
mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with
chronic, non-cancer pain. The product is also approved in
the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. The AstraZeneca agreement also includes
NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a collaboration
agreement with Baxalta for ADYNOVATE™ [Antihemophilic Factor
(Recombinant)], a longer-acting PEGylated Factor VIII therapeutic
approved in the U.S. in patients over 12 with hemophilia
A. In anti-infectives, Amikacin Inhale is in Phase 3 studies
conducted by Bayer Healthcare as an adjunctive treatment
for intubated and mechanically ventilated patients with
Gram-negative pneumonia.
Nektar's technology has enabled nine approved products
in the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE™, UCB's CIMZIA® for Crohn's disease
and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and
Amgen's NEULASTA® for neutropenia.
Nektar is headquartered in San Francisco, California, with additional operations
in Huntsville, Alabama, and Hyderabad, India. Further information about the company
and its drug development programs and capabilities may be found
online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE™ is a trademark of Baxalta Inc.
Contact:
For Investors and Media:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2015-on-tuesday-march-1-2016-after-close-of-us-based-financial-markets-300227081.html
SOURCE Nektar Therapeutics